Skip Navigation

A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards and Recognition

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.


Guided by our values, our employees work every day to make meaningful differences in healthcare. At the core of what we do is our most valuable resource - our people. Learn more about us.

Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Working closely with our members, we're developing products and services to solve your most complex challenges.

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

The proactive, predictive and behind-the-scenes insights you need to stay ahead in healthcare delivered monthly to your inbox.

Premier Comments on FDA Compounding Draft Guidance

Premier submitted comments in response to the FDA’s draft guidance on the statutory prohibition on wholesaling for certain compounded drugs in which the agency outlines how it intends to apply the prohibition that was enacted under Section 503B of the Federal Food, Drug, and Cosmetic Act. In its comments, Premier urges the FDA to:

  • Clarify that the definition of “dispense” is distinct and different from the term “resale” and that products labeled “not for resale” can be dispensed pursuant to a patient-specific prescription;
  • Define “intracompany transfer” and adopt the National Association of Boards of Pharmacy (NABP) model pharmacy act definition of “meaning any transfer between a division, subsidiary, parent, and/or affiliated or related company under the common ownership and control of a corporate entity” to remove any confusion regarding what constitutes an appropriate transfer of a compounded drug; and
  • Reverse its interpretation of the wholesaler prohibition as it relates to marketing firms, which currently includes third party entities that provide administrative support to a 503B outsourcing facility, even if the third party does not take possession of the compounded product.

Premier will continue to actively engage with our members as they leverage compounding to combat drug shortages while a longer-term strategy is being developed. To this end, Premier:

  • Maintains a network of 503B outsourcing facilities to compound products using current good manufacturing practices (cGMP) and personally audits every 503B outsourcing facility it contracts with using an assessment tool that goes above and beyond FDA and State Board of Pharmacy requirements;
  • Created a health system-led 503B Advisory Group for insights on outsourcing needs and supplier challenges to support managing supply disruptions, including insource compounding guidance and available alternatives on the market; and
  • Engages with the FDA and sits on the FDA Compounding Center of Excellence workgroup where it helps federal partners understand the impact of 503B regulatory decisions on drug shortages and patient care.
Login Register Change Registration